All In Biotech

Drug Trial Radar · NCT04811716

Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

A Randomized, Open-label, Two-arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

Jul 29, 2021

Primary completion

Oct 25, 2022

Study completion Oct 18, 2023

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the safety and tolerability of 2 dosing regimens of pozelimab and cemdisiran combination therapy during the open-label treatment period (OLTP) The secondary objectives of the study are: * To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of total complement hemolysis activity (CH50) * To evaluate the effect of the combination treatment on hemoglobin levels * To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements * To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life * To assess the concentrations of total pozelimab in serum and total complement component (C) 5 and cemdisiran in plasma * To assess immunogenicity to pozelimab and cemdisiran * To evaluate the long-term safety and efficacy of pozelimab and cemdisiran in an optional open-label extension period (OLEP) * To assess safety after treatment intensification with pozelimab and cemdisiran

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • PozelimabDrug

    Administered Sub-cutaneous (SC) per protocol

  • CemdisiranDrug

    Administered SC per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: Through Week 28

Locations

13 sites in 6 countries. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, New Territories, Hong Kong

  • D l Pesti Centrumk rh z Orsz gos Hematol giai s Infektol giai Int zet

    Budapest, Nagyvárad Tér 1, Hungary

  • Hospital Miri

    Miri, Sarawak, Malaysia

  • Hospital Sibu

    Sibu, Sarawak, Malaysia

  • Hospital Sultanah Nur Zahirah

    Kuala Terengganu, Terengganu, Malaysia

  • Pusan National University Hospital

    Busan, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Yonsei University College of Medicine, Severance Hospital

    Seoul, South Korea

  • Ewha Womans University Medical Centre

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, Seoul Teugbyeolsi, South Korea

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Chang Gung Memorial Hospital

    Taoyuan City, Taiwan

  • St. James's University Hospital

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.